Page last updated: 2024-08-24

2-methoxyestradiol and fluorodeoxyglucose f18

2-methoxyestradiol has been researched along with fluorodeoxyglucose f18 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arnott, J; Hahn, NM; Hammers, H; Harrison, MR; Kim, K; Liu, G; Oh, WK; Perlman, S; Pili, R; Sidor, C; Sweeney, C; Wilding, G	1

Trials

1 trial(s) available for 2-methoxyestradiol and fluorodeoxyglucose f18

Article	Year
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational new drugs, 2011, Volume: 29, Issue:6 Topics: 2-Methoxyestradiol; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Estradiol; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nanoparticles; Neoplasm Metastasis; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Treatment Outcome	2011

Article

Year

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Investigational new drugs, 2011, Volume: 29, Issue:6

Topics: 2-Methoxyestradiol; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Estradiol; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nanoparticles; Neoplasm Metastasis; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Treatment Outcome

2011